Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...
The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) as a preventative measure against potential pulmonary ...
Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism ...
Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for Eliquis ...
The novel oral anticoagulant apixaban has similar effects on stroke, systemic embolism and major bleeding in patients with atrial fibrillation (A-fib) whether they have been on previous warfarin ...
U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin ...
Please provide your email address to receive an email when new articles are posted on . Data suggest that apixaban, a direct oral anticoagulant, may be preferable to other drugs in its category as it ...
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac ...
Apixaban is a cost-effective alternative to warfarin in warfarin-suitable candidates and also compares well with aspirin in patients who cannot take the vitamin K antagonist. The findings, derived ...
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that with
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and Pfizer Inc. (NYS: PFE) today announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial.
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback